On Tuesday, Jefferies updated its assessment of Praxis Precision Medicines Inc. (NASDAQ:PRAX), elevating the stock price target to $128 from the previous $75 while maintaining a Buy rating on the stock. This adjustment follows the announcement that PRAX-628 demonstrated complete suppression in the 45 mg cohort, surpassing expectations.
The successful results of PRAX-628 have cleared the way for Praxis to proceed to a Phase 2b trial for focal epilepsy in the second half of 2024, with the potential to expand into generalized epilepsy trials. The analyst from Jefferies highlighted that the positive proof-of-principle (PPR) data bolsters the outlook for PRAX, anticipating further momentum with upcoming milestones.
These include the Phase 2 readout for PRAX-562 in developmental and epileptic encephalopathies (DEE) expected around mid-2024, and the Phase 3 topline results for Ulixa in essential tremor (ET) in the latter half of the year.
In response to these developments, Jefferies has revised its model for Praxis, increasing the probability of success (PoS) for both PRAX-628 and Ulixa. This revision underpins the raised price target, reflecting a more optimistic view of the company’s prospects.
The analyst’s statement underscored the significance of the recent data and its impact on the valuation, “With PPR data confirmed we see continued positive momentum for PRAX with upcoming catalysts including: Ph2 PRAX-562/DEE readout mid-24 and Ph3 Ulixa/ET topline in 2H24. We update our model to increase PoS for ‘628 and Ulixa, which raises our PT to $128.”
Praxis Precision Medicines specializes in the development of treatments for central nervous system disorders and has been actively advancing its pipeline of potential therapies. The recent updates are particularly crucial as they suggest a promising path forward for the company’s investigational drugs.
The market will be closely monitoring the progress of these trials, as indicated by the revised price target and the sustained Buy rating from Jefferies.
InvestingPro Insights
As Praxis Precision Medicines Inc. (NASDAQ:PRAX) navigates through pivotal trials and key milestones, real-time data from InvestingPro provides a snapshot of the company’s financial health and market performance. With a market capitalization of $780.67 million, Praxis holds a notable position in the biotech industry.
Despite a negative Price-to-Earnings (P/E) ratio of -3.12, indicating that the company is not currently profitable, the significant year-to-date price total return of 126.66% reflects strong investor confidence in the company’s future prospects, bolstered by recent trial successes.
InvestingPro Tips highlight that Praxis holds more cash than debt on its balance sheet, a sign of financial stability, and that analysts have revised their earnings upwards for the upcoming period, signaling potential optimism in the company’s financial future. However, it’s important to note that analysts do not anticipate the company will be profitable this year, and they expect a sales decline in the current year.
Praxis also faces challenges with cash burn and weak gross profit margins. The company’s stock price has been volatile, yet it has seen a high return over the last year, and liquid assets exceed short-term obligations. These metrics and insights, including several additional tips available on InvestingPro, can guide investors in their decision-making process. For those looking for deeper analysis, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
